Pentosan Polysulfate Sodium

Structure: Semi-synthetic sulfated polysaccharide (polysulfated xylan) derived from beechwood hemicellulose. Structurally similar to heparin and to the glycosaminoglycans found in cartilage, which is why it carries both chondroprotective and anticoagulant properties.

Dosage:

• Osteoarthritis (clinical trial protocol): 2mg/kg SubQ twice weekly for 6 weeks, then a treatment-free interval. This is the Paradigm Biopharma knee OA dosing used in the PARA_OA trials.
• Registered Australian label (Zilosul): 1-2mg/kg IM once weekly for 4 injections.
• Repeat courses: typically no more sooner than every 6 months; many users go 12-24 months between courses as symptoms dictate.
• Oral (Elmiron, interstitial cystitis): 100mg three times daily. Different indication, different risk profile.

Administration:

• SubQ (abdomen) or IM (gluteal/deltoid), 27-30g insulin syringe for SubQ
• Dose is weight-based, so recalculate if bodyweight has shifted meaningfully since the last course
• Do not inject on the same day as a heavy NSAID load if you bruise easily; the anticoagulant effect is additive

Key Notes:

• Mechanism is multi-modal: stimulates hyaluronan and proteoglycan synthesis in synoviocytes, inhibits catabolic enzymes (MMPs, aggrecanase), inhibits complement activation, and has a fibrinolytic effect that improves subchondral bone blood flow. It is a disease-modifying agent, not an analgesic, so relief builds over weeks rather than days.
• Human evidence for injectable PPS in knee osteoarthritis is Phase 2/3 stage and reports pain and function improvement that persists for months after the 6-week course ends.
• Bleeding risk is the main practical concern. PPS is a heparinoid. Combining it with NSAIDs, aspirin, fish oil at high doses, or any anticoagulant raises bleeding risk. Stop before elective surgery or dental extraction.
• Rare but serious: immune-mediated thrombocytopenia. A HIT-like reaction has been reported. A falling platelet count during or shortly after a course is a stop signal, not something to ride out.
• Long-term high cumulative oral exposure (Elmiron, typically years and hundreds of grams cumulative) is associated with pigmentary maculopathy, a retinal toxicity. This has not been reported with short injectable courses, but it is a reason not to run oral PPS open-ended.
• Veterinary formulations (Cartrophen Vet, Zydax) are widely diverted for human use because they are cheap and easy to obtain. The active ingredient is the same, but sterility, concentration accuracy, and excipients are not held to human standards.
• Not hormonal and not suppressive. It can be run alongside TRT, a cycle, or healing peptides without interaction on the endocrine side.
• Commonly stacked with BPC-157 and TB-500 for joint and connective tissue work; PPS targets the cartilage matrix while those target soft tissue repair.

Bloodwork Monitoring:

• Baseline: Platelets and APTT before starting, particularly if you have run PPS before or have any bleeding history.
• Mid-course (around week 3): repeat platelets. A drop of more than 30-50% from baseline warrants stopping and a clinician review.
• On-course: a modestly prolonged APTT is expected and is not itself a reason to stop. Interpret it alongside symptoms (unusual bruising, gum bleeding, prolonged bleeding from injection sites).
• ALT and AST: worth including if you are running oral PPS or stacking with 17-alpha-alkylated orals.
• No changes needed to hormone, lipid, or thyroid monitoring on account of PPS.